Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
ID07274397

Assessment of Early Post-operative Nuclear Imaging in Neurosurgery: a Safety and Feasibility Study in Patients Operated for Glioblastoma

Led by Beta Emitting Accurate Monitored Systems · Updated on 2026-06-08

15

Participants Needed

1

Research Sites

N/A

Total Duration

On this page

Sponsors

B

Beta Emitting Accurate Monitored Systems

Lead Sponsor

A

Assistance Publique - Hôpitaux de Paris

Collaborating Sponsor

AI-Summary

What this Trial Is About

Researchers are evaluating the safety and feasibility of early post-operative brain PET-MRI imaging in adults who have undergone surgery for suspected glioblastoma. The study aims to validate specific nuclear imaging parameters to improve detection of residual tumor tissue compared to standard gadolinium-enhanced MRI. This prospective interventional diagnostic study will include 15 patients at a single site in France, focusing on imaging within 48 hours after surgery and monitoring for side effects related to the imaging procedures. Participants will undergo combined PET-MRI imaging using 18F-DOPA as the radiotracer and gadolinium-based contrast for MRI enhancement. The PET scan involves an intravenous injection of 18F-DOPA at 2 MBq/kg with static brain acquisition starting immediately after injection. MRI sequences include diffusion, spectroscopy, perfusion, and angiography scans. Patients will be monitored for radiation exposure and any adverse events during and after imaging, with a total monitoring period of 24 hours post-procedure. During the study, participants receive a pre-surgical baseline evaluation including medical history, PET-MRI, and MRI scans within 30 days to 2 days before surgery. After surgery, informed consent is obtained, followed by post-operative PET-MRI imaging and monitoring in the nuclear medicine department. Dosimetry measurements occur over 24 hours to assess radiation exposure. Safety assessments include observation for hypersensitivity or side effects related to gadolinium or 18F-DOPA. The study lasts approximately 24 hours per patient, with follow-up managed by the usual neurosurgical care team.

CONDITIONS

Brief Title

Assessment of Early Post-operative Nuclear Imaging in Neurosurgery: a Safety and Feasibility Study in Patients Operated for Glioblastoma

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • First resection for a suspected glioblastoma in the past 72 hours
  • Signed informed consent
  • Adults aged 18 years or older
Not Eligible

You will not qualify if you...

  • Deprived of liberty or under legal protection (e.g, guardianship, trusteeship)
  • Patients under 18 years old
  • Absence of social security cover
  • Pregnancy
  • Emergency procedure
  • Contraindication to brain MRI, including claustrophobia
  • Contraindication to radiotracers or gadolinium injection
  • Preoperative cognitive impairment impeding patient information
  • Any postoperative behavioral disorders or medical condition impeding brain imaging
  • Postoperative medical dependency preventing transfer to nuclear medicine
  • Postoperative histological diagnosis different from glioblastoma

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 to 2 visits including pre-surgical baseline evaluation within 30 to 2 days prior to surgery

Surgery

Duration - 1 day

Participants undergo neurosurgical procedure for tumor resection under general anesthesia.

Surgery day (in-person)

Early Post-operative Imaging

Duration - Up to 2 days

Participants receive early post-operative brain PET-MRI imaging with 18F-DOPA and gadolinium-based contrast within 48 hours after surgery. Radiation exposure and potential adverse events related to imaging agents are monitored.

1 visit including radiotracer injection, PET-MRI acquisition, and monitoring for at least 30 minutes post-imaging

Post-imaging Monitoring

Duration - 24 hours

Participants are monitored for 24 hours post imaging to assess radiation dosimetry and safety outcomes.

Continuous monitoring over 24 hours with dosimeter measurements

Trial Site Locations

Total: 1 location

1

Hôpital Henri Mondor - Université Paris-Est Créteil (UPEC)

Créteil, France, 94010

Actively Recruiting

Loading map...

Research Team

C

Caroline Apra, MD, PhD

N

Nawel Saci, Msc

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

DIAGNOSTIC

Number of Arms

1

Similar Trials

A Phase 1 Safety and Dose Finding Study of 131I-TLX101 Plus ...

Neoplastic Disease

Actively Recruiting

6 locations

A Phase 0/1 Study of BDTX-1535 in Recurrent High-Grade Gliom...

High Grade Glioma

Actively Recruiting

2 locations

An Open-Label Phase 1 Safety and Dose Finding Study of Orall...

Glioblastoma Multiforme of Brain

Actively Recruiting

3 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here